Cronos Group Inc.

Report azionario TSX:CRON

Capitalizzazione di mercato: CA$1.4b

Cronos Group Crescita futura

Criteri Future verificati 4/6

Si prevede che Cronos Group aumenterà gli utili e i ricavi rispettivamente del 36.3% e 6.4% all'anno, mentre si prevede che l'EPS crescerà del 39.2% all'anno.

Informazioni chiave

36.3%

Tasso di crescita degli utili

39.23%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili31.8%
Tasso di crescita dei ricavi6.4%
Rendimento futuro del capitale proprion/a
Copertura analitica

Low

Ultimo aggiornamento12 May 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Aggiornamento della narrazione • May 12

CRON: Partial Rescheduling And Brand Execution Will Shape Lean Profit Outlook

Analysts have lifted their fair value estimate for Cronos Group from CA$3.19 to CA$3.45, citing recent initiation with a CA$4.50 price target and the view that branded positioning, a lean cost base, and potentially favorable regulatory shifts could support higher long term profitability and a lower future P/E assumption. Analyst Commentary Recent commentary around Cronos Group has focused on brand strength, cost discipline, and the potential impact of regulatory changes in key markets.
Aggiornamento della narrazione • Apr 25

CRON: Partial Rescheduling Hopes Will Test Lean Cost Base Execution

Analysts have raised their Cronos Group price target to CA$4.50, citing expectations for slightly stronger revenue growth, modestly better profit margins, and a lower assumed future P/E, following recent bullish coverage and a favorable view on partial cannabis rescheduling. Analyst Commentary Recent research coverage on Cronos Group has centered on how potential regulatory shifts and brand positioning could influence the company’s path to improved profitability and valuation.
Aggiornamento della narrazione • Apr 11

CRON: Canadian Brand Strength And Lean Cost Base Will Support Future Upside

Analysts have reset their price target for Cronos Group to CA$4.50, reflecting fresh coverage that highlights the company’s established Canadian brands, its focus on scaling revenue with a lean cost base, and cultivation practices that are expected to support profitability trends. Analyst Commentary Recent coverage frames Cronos Group as a company with established Canadian brands and a focus on keeping its cost base lean while scaling revenue.
Aggiornamento della narrazione • Mar 28

CRON: Lean Cost Base And Brand Execution Will Shape Future Earnings Potential

Analysts have lifted their average price target for Cronos Group to CA$4.50, citing expectations for faster top line expansion, a leaner cost base and stronger profitability potential supported by the company's established Canadian cannabis brands and cultivation practices. Analyst Commentary Recent Street research has framed Cronos Group as a branded cannabis operator with established products in Canada and an emphasis on scaling revenue while keeping operating costs in check.
Aggiornamento della narrazione • Mar 13

CRON: Canadian Brand Strength And Rescheduling Shift Will Support Future Upside

Analysts have lifted their CA$ price target on Cronos Group, citing the company's Canadian cannabis brands, expectations for better profitability as revenue grows against a lean cost base, and confidence in its cultivation practices as key supports for the higher valuation range. Analyst Commentary Bullish Takeaways Bullish analysts highlight Cronos Group's portfolio of Canadian cannabis brands as a key support for the higher CA$ valuation range, arguing that strong consumer recognition can help sustain revenue as the company scales.
Aggiornamento della narrazione • Feb 27

CRON: Canadian Brand Strength And Rescheduling Shift Will Reshape Risk Reward Profile

Analysts have lifted their fair value estimate for Cronos Group to CA$4.24 from CA$3.95, pointing to higher assumed revenue growth and a lower future P/E multiple. They are factoring in recent bullish coverage highlighting the company’s established Canadian cannabis brands, lean cost base, and cultivation practices.
Aggiornamento della narrazione • Feb 13

CRON: Rescheduling Shift Will Expose Execution Risks And Restrain Earnings Upside

Analysts have lifted their CA$ fair value estimate for Cronos Group to CA$3.19, citing Street research that points to slightly higher expected revenue growth, modestly stronger profit margins, and a marginally lower future P/E assumption that together support a more constructive long term outlook. Analyst Commentary While the higher CA$3.19 fair value estimate reflects a more constructive stance on Cronos Group, not all research is leaning in the same direction.
Aggiornamento della narrazione • Jan 30

CRON: Rescheduling Shift And Product Expansion Will Shape A Balanced Earnings Outlook

Analysts have raised their price target on Cronos Group by a small amount to reflect updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a marginally higher future P/E multiple. Analyst Commentary While some research points to a constructive view on Cronos Group, bearish analysts highlight a set of risks that could limit upside and keep the stock more range bound.
Aggiornamento della narrazione • Jan 16

CRON: Rescheduling Policy Shift Will Temper Optimism On Future Earnings Profile

Analysts have raised their price target for Cronos Group to US$3.19 from US$2.90, pointing to updated assumptions around slightly higher discount rates, more conservative revenue growth and a modestly stronger profit margin profile, alongside a similar forward P/E outlook. What's in the News President Trump directed the Attorney General to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act, which directly touches U.S. cannabis policy and mentions Cronos Group among other publicly traded peers in the sector (Marijuana Herald).
Articolo di analisi • Dec 13

Cronos Group Inc. (TSE:CRON) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected

Cronos Group Inc. ( TSE:CRON ) shareholders have had their patience rewarded with a 29% share price jump in the last...
Aggiornamento della narrazione • Sep 04

GrowCo Capacity And Global Markets Will Unlock Potential

The Consensus Analyst Price Target for Cronos Group has increased to CA$3.95, primarily reflecting a notable rise in the company's Future P/E multiple despite stable revenue growth expectations. What's in the News President Trump is considering reclassifying marijuana as a less dangerous drug, which could ease restrictions and benefit cannabis companies such as Cronos Group (The Wall Street Journal).
Articolo di analisi • Aug 15

Cronos Group Inc.'s (TSE:CRON) 26% Share Price Surge Not Quite Adding Up

Cronos Group Inc. ( TSE:CRON ) shareholders would be excited to see that the share price has had a great month, posting...
User avatar
Nuova narrazione • Apr 30

GrowCo Expansion Will Boost Operations But Strain Cash Flow

Investment in GrowCo and advancements in cannabis genetics are set to improve efficiency, enhance profitability, and strengthen market penetration.
Articolo di analisi • May 31

We're Interested To See How Cronos Group (TSE:CRON) Uses Its Cash Hoard To Grow

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Apr 01

Cronos Group Inc.'s (TSE:CRON) P/S Is Still On The Mark Following 29% Share Price Bounce

The Cronos Group Inc. ( TSE:CRON ) share price has done very well over the last month, posting an excellent gain of...
Articolo di analisi • Mar 02

We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Feb 02

Revenues Tell The Story For Cronos Group Inc. (TSE:CRON)

When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...
Articolo di analisi • Nov 09

Companies Like Cronos Group (TSE:CRON) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Jul 17

We're Hopeful That Cronos Group (TSE:CRON) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Articolo di analisi • Jun 20

Cronos Group Inc.'s (TSE:CRON) Earnings Haven't Escaped The Attention Of Investors

When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...

Previsioni di crescita degli utili e dei ricavi

TSX:CRON - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20282215868712
12/31/20272193946613
12/31/20261923052434
12/31/2025147-9026N/A
9/30/202513236-622N/A
6/30/202513018-920N/A
3/31/202512549-819N/A
12/31/202411841619N/A
9/30/2024111-481728N/A
6/30/2024102-571116N/A
3/31/202493-54-23N/A
12/31/202387-70-46-43N/A
9/30/202385-101-86-84N/A
6/30/202381-133-101-97N/A
3/31/202384-145-108-103N/A
12/31/202287-155-94-89N/A
9/30/202291-213-105-101N/A
6/30/202291-102-124-119N/A
3/31/202285-263-147-141N/A
12/31/202165-127-166-154N/A
9/30/202166-373-179-156N/A
6/30/202157-381-181-153N/A
3/31/202151-310-188-153N/A
12/31/202047-72-180-145N/A
9/30/202037101-185-160N/A
6/30/202031636-186-152N/A
3/31/202029929-192-155N/A
12/31/2019241,167-170-131N/A
9/30/2019211,089N/A-59N/A
6/30/201918479N/A-49N/A
3/31/201913293N/A-11N/A
12/31/201812-21N/A-8N/A
9/30/20189-8N/A-28N/A
6/30/20187-1N/A-16N/A
3/31/20185-2N/A-13N/A
12/31/20173-1N/A-4N/A
9/30/201741N/A-4N/A
6/30/201720N/A-8N/A
3/31/20171-1N/A-6N/A
12/31/20160-1N/A-5N/A
9/30/201620N/A-3N/A
6/30/201620N/A-2N/A
3/31/201631N/A-1N/A
12/31/201520N/A-1N/A
9/30/20150-4N/A-2N/A
6/30/2015-1-4N/A-2N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che CRON diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 3% ).

Guadagni vs Mercato: Si prevede che CRON diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede CRON diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di CRON ( 6.4% all'anno) crescerà più rapidamente del mercato Canadian ( 4.5% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di CRON ( 6.4% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di CRON è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/22 03:18
Prezzo dell'azione a fine giornata2026/05/22 00:00
Utili2025/12/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Cronos Group Inc. è coperta da 16 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Jesse PytlakATB Cormark Historical (Cormark Securities)
Vahan AjamianBeacon Securities Limited
Nadine SarwatBernstein